Inyx Inc., of New York, appointed Duncan McIntyre managing director of Inyx Europe Ltd.
MedImmune Inc., of Gaithersburg, Md., appointed John Trizzino vice president, trade and distribution, and Mark Twyman vice president and general manager, vaccines. It also promoted Frank Czworka to vice president, sales, infectious disease; and it added four other new vice presidents: Allan Darling for corporate quality control, Garry Ebbert for antibody and small-molecule manufacturing, Bahija Jallal for translational sciences, and Douglas Willner for sales training.
Mersana, of Cambridge, Mass., appointed Russell Petter vice president of research and Ullrich Schwertschlag vice president of clinical development.
Metabasis Therapeutics Inc., of San Diego, appointed Constance Bienfait vice president of investor relations and corporate communications.
Microbia Inc., of Cambridge, Mass., appointed George Conrades to its board.
MicroIslet Inc., of San Diego, appointed Bertram Walls an independent member of its board.
Morphotek Inc., of Exton, Pa., appointed Robert Radie chief business officer, and promoted Luigi Grasso to senior vice president of research and development.
Myriad Genetics Inc., of Salt Lake City, appointed Jose Fojas vice president of marketing for Myriad Pharmaceuticals Inc.
Novacea Inc., of South San Francisco, appointed Amar Singh chief commercialization officer.
Nuvelo Inc., of San Carlos, Calif., appointed Shelly Guyer vice president, business development and investor relations.
Orexigen Therapeutics Inc., of San Diego, appointed Gary Tollefson president and CEO.
Othera Pharmaceuticals Inc., of Exton, Pa., appointed Al Reaves senior vice president of clinical development.
Par Pharmaceutical Companies Inc., of Spring Valley, N.Y., appointed Gerard Martino vice president and chief financial officer.
PDL BioPharma Inc., of Fremont, Calif., appointed Andrew Guggenhime senior vice president and chief financial officer.
Pharmaxis Ltd., of Sydney, Australia, appointed Peter Farrell to its board.
ProtAffin Biotechnologie AG, of Graz, Austria, appointed to its scientific advisory board Robert Huber, Detlef Schlöndorff and John Gallagher.
Protemix, of San Diego, appointed Alan Cherrington and Daniel Petree to its board.
Quintiles Transnational Corp., of Research Triangle Park, N.C., appointed Yoh Narimatsu president and CEO of Quintiles Transnational Japan KK.
Scynexis Inc., of Research Triangle Park, N.C., appointed Pamela Kirby chairman of its board.
Seattle Genetics Inc., of Bothell, Wash., appointed Daniel Hoth to its board.
Sirna Therapeutics, of San Francisco, appointed to its scientific advisory board Keith Yamamoto as chair, and Jeffrey Bluestone, Beverly Davidson, Donald Ganem, Joe Gray, Stanley Lemon, Richard Locksley, Jerrold Olefsky, David Russell, Xiaodong Wang and James Wells as members.